Free Trial

Impax Asset Management Group plc Lowers Stock Position in Repligen Corporation (NASDAQ:RGEN)

Repligen logo with Medical background

Impax Asset Management Group plc decreased its holdings in Repligen Corporation (NASDAQ:RGEN - Free Report) by 23.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 804,511 shares of the biotechnology company's stock after selling 247,428 shares during the quarter. Impax Asset Management Group plc owned about 1.43% of Repligen worth $101,491,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in RGEN. Price T Rowe Associates Inc. MD boosted its position in shares of Repligen by 11.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock worth $1,027,165,000 after purchasing an additional 743,815 shares in the last quarter. Point72 Asset Management L.P. raised its stake in Repligen by 183.1% in the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock worth $132,227,000 after acquiring an additional 594,189 shares during the last quarter. Groupama Asset Managment raised its stake in Repligen by 12,321.0% in the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company's stock worth $58,142,000 after acquiring an additional 400,680 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in Repligen in the 4th quarter worth $53,428,000. Finally, Raymond James Financial Inc. purchased a new position in Repligen in the 4th quarter worth $52,492,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. HC Wainwright restated a "buy" rating and issued a $180.00 target price on shares of Repligen in a research note on Monday, May 5th. Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Royal Bank Of Canada reduced their target price on Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research note on Wednesday, April 30th. Barclays assumed coverage on Repligen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 target price for the company. Finally, Canaccord Genuity Group reduced their target price on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research note on Wednesday, April 16th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, Repligen has an average rating of "Moderate Buy" and an average price target of $172.83.

Check Out Our Latest Report on RGEN

Repligen Stock Up 0.3%

Shares of RGEN stock traded up $0.40 on Friday, reaching $127.36. 208,766 shares of the stock were exchanged, compared to its average volume of 729,442. The business's 50 day moving average price is $126.70 and its 200 day moving average price is $139.87. The company has a market capitalization of $7.16 billion, a price-to-earnings ratio of -283.02, a PEG ratio of 3.65 and a beta of 1.11. Repligen Corporation has a twelve month low of $102.97 and a twelve month high of $182.52. The company has a current ratio of 6.79, a quick ratio of 5.79 and a debt-to-equity ratio of 0.27.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.04. The company had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The business's quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.28 earnings per share. As a group, sell-side analysts expect that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

About Repligen

(Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Featured Stories

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Should You Invest $1,000 in Repligen Right Now?

Before you consider Repligen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.

While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines